Bartholin's gland squamous cell carcinoma.

University of Nottingham, Nottingham, UK.
Journal of Obstetrics and Gynaecology (Impact Factor: 0.6). 04/2012; 32(3):318-9. DOI: 10.3109/01443615.2011.652703
Source: PubMed
  • [Show abstract] [Hide abstract]
    ABSTRACT: Fourteen cases of primary carcinoma of the Bartholin gland were treated between 1955 and 1980. Follow-up information was available on all patients. Ten patients have survived free of disease for 5 or more years. Three patients with positive inguinal lymph nodes have survived 5 years. Histologic patterns and lymph node involvement are analyzed. The authors[spacing acute] data and a review of the literature support the concept that radical vulvectomy with bilateral inguinalfemoral lymphadenectomy is required for all histologic types of Bartholin gland carcinoma. Routine pelvic lymph node dissection is not necessary when the inguinal-femoral nodes are negative for metastases. (C) 1982 The American College of Obstetricians and Gynecologists
    Obstetrics and Gynecology 08/1982; 60(3). · 4.37 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: During the last decades there has been a continuing evolution in the surgical approach of squamous cell carcinoma of the vulva that has been traditionally treated with radical vulvectomy and bilateral inguinal-femoral lymphadenectomy. Patients with T1 tumour are usually treated with radical local excision, if the lesion is unifocal and the remainder of the vulva is normal. Patients with T1a disease have no risk of groin metastases and do not need lymphadenectomy, whereas those with T1b disease need ipsilateral inguinal-femoral lymphadenectomy if the lesion is lateral, and bilateral lymphadenectomy if the lesion is midline. Modifications of the surgical technique of deep femoral lymphadenectomy and the mapping of sentinel node can offer new interesting therapeutic perspectives. Postoperative adjuvant pelvic and groin irradiation is warranted for patients with two or more or macroscopically involved groin nodes. Locally advanced squamous cell carcinoma of the vulva has been long surgically treated with en-block radical vulvectomy and bilateral inguinal-femoral lymphadenectomy plus partial resection of urethra, vagina or anum, or by exenteration, with severe postsurgical complications, poor quality of life, and unsatisfactory survival rates. 5-Fluorouracil [5-FU] or 5-FU- and cisplatin-based chemotherapy concurrent with irradiation followed by tailored surgery represents an attractive therapeutic option for advanced disease, planned to avoid such ultra-radical surgical procedures and, hopefully, to improve patient outcome. Chemotherapy has also been used in neoadjuvant setting, with contrasting and generally unsatisfactory results, and in palliative treatment of patients with distant metastases. Surgery is the primary treatment also for vulvar malignancies other than squamous cell carcinoma, whereas the clinical usefulness of adjuvant irradiation or chemotherapy is still to be defined. Primary chemoradiation can be also used for advanced carcinoma of the Bartholin gland or for advanced adenocarcinoma associated with extramammary Paget's disease. The drugs used for chemotherapy of metastatic melanomas or sarcomas of the vulva are the same employed for the melanomas or sarcomas developed in other sites.
    Critical Reviews in Oncology/Hematology 01/2007; 60(3):227-41. DOI:10.1016/j.critrevonc.2006.06.009 · 4.05 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Optimal management of carcinoma of the Bartholin gland is not yet defined. Patients with locally advanced disease have historically been managed by radical and, occasionally, exenterative surgery. Although the management of advanced vulvar cancer has shifted toward conservative management with primary chemoradiation, there is limited information on the similar approach to the management of advanced Bartholin's gland carcinoma. We present a woman with stage IVA basaloid squamous carcinoma of the Bartholin gland. She was managed with primary chemoradiation in an attempt to spare her the morbidity associated with exenterative surgery. We discuss a rationale for the use of chemoradiation in advanced Bartholin's gland carcinoma. Conservative management of advanced carcinoma of the Bartholin gland with primary chemoradiation may be appropriate while sparing patients the sequelae of exenterative surgery.
    Gynecologic Oncology 12/2002; 87(2):210-2. DOI:10.1006/gyno.2002.6787 · 3.69 Impact Factor